Disitamab Vedotin Of Injection: A ‘Bio-Missile’ For Cancer Treatment
Disitamab vedotin of injection is a drug used for the treatment of several solid tumours.
It is an antibody-drug coupling consisting of an immunoglobulin G1 antibody linked to the anti-tumour drug vedotin (monomethylated sage E).
Disitamab Vedotin Of Injection: A ‘Bio-Missile’ To Fight Cancer Cells With Precision.
Disitamab vedotin of injection is an antibody-coupled drug (ADC) that acts as a precise ‘biological missile’, specifically recognising and binding to targets on the surface of cancer cells, and then delivering the potent cytotoxic drug to the cancer cells to kill them.
The drug is then precisely delivered to the cancer cells to play a killing role.
This precise targeted therapy not only improves the killing effect of drugs on cancer cells, but also minimises the damage to normal cells, thus reducing the side effects of drugs and improving patients’ tolerance and quality of life.
Compared with traditional chemotherapy drugs, Disitamab vedotin of injection has higher selectivity and stronger anti-tumour activity.
The results of preclinical studies have shown that the drug has demonstrated significant tumour-suppressive effects in a variety of cancer models, laying a solid foundation for its subsequent clinical trials and clinical application.
Disitamab Vedotin Of Injection: A Breakthrough Therapy
Disitamab vedotin injection is an antibody-drug coupling targeting HER2 (Human Epidermal Growth Factor Receptor 2).
HER2 is a protein that is closely associated with the development and progression of malignant tumours in a variety of cancer types, particularly breast, gastric and non-small cell lung cancers.
Disitamab vedotin of injection significantly improves therapeutic targeting and killing by combining antibodies with cytotoxic drugs to precisely deliver the drugs into the tumour cells and reduces damage to normal cells.
The launch of Disitamab vedotin injection is particularly important for the treatment of patients with HER2-positive tumours.
However, DengYue‘s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it. So please feel free to inquiry us for Disitamab.
Information from DengYueMed, offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
